{Reference Type}: Journal Article
{Title}: METFORMIN MODULATED ADIPOKINES BIOCHEMICAL MARKERS IN TYPE-2 DIABETES PATIENTS.
{Author}: Toaama H;Sarhat E;Mohammed H;
{Journal}: Georgian Med News
{Volume}: 0
{Issue}: 350
{Year}: 2024 May
暂无{Abstract}: Type 2 diabetes mellitus is the most widespread type of diabetes, mainly affecting adults. Long-term complications are related to the progression of type 2 diabetes mellitus. Metformin is a key treatment option for type 2 diabetes.<BR><B>OBJECTIVE: </B>To evaluate serum irisin, visfatin, and RBP4 levels and to determine the effects of metformin treatment on irisin, visfatin, and RBP4 levels in patients with type 2 diabetes mellitus (Type 2 DM).<BR><B>METHODS: </B>A total of 70 patients with type 2 diabetes mellitus, aged between 48 and 82 years were enrolled in the current study. Serum collected and irisin, visfatin, and RBP4 levels were measured, in Type 2 DM patients and control, using the ELISA Kit.<BR><B>RESULTS: </B>The findings observed that there were significantly increased levels of irisin, visfatin, and RBP4 in patients with T2DM when compared with control groups. After 3 months of metformin treatment, irisin levels significantly decreased irisin, visfatin, and RBP4 in patients with T2DM when compared before treatment. Receiver operator characteristic curve investigation shows the levels of visfatin, and irisin are the best biomarkers differentiating subjects with T2DM.<BR><B>CONCLUSIONS: </B>In patients with type 2 diabetes, 3 months of treatment with metformin reduces levels of Irisin, Visfatin, and RBP4.The clinical significance of these findings remains to be investigated.